JP6952691B2 - Ｂ−ｒａｆ阻害剤及び免疫チェックポイント阻害剤を使用してがんを治療する方法 - Google Patents

Ｂ−ｒａｆ阻害剤及び免疫チェックポイント阻害剤を使用してがんを治療する方法 Download PDF

Info

Publication number
JP6952691B2
JP6952691B2 JP2018525700A JP2018525700A JP6952691B2 JP 6952691 B2 JP6952691 B2 JP 6952691B2 JP 2018525700 A JP2018525700 A JP 2018525700A JP 2018525700 A JP2018525700 A JP 2018525700A JP 6952691 B2 JP6952691 B2 JP 6952691B2
Authority
JP
Japan
Prior art keywords
vemurafenib
effective amount
dose
cobimetinib
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018525700A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018534311A5 (enExample
JP2018534311A (ja
Inventor
ドーン コルバーン，
ドーン コルバーン，
ニコール リッチー，
ニコール リッチー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2018534311A publication Critical patent/JP2018534311A/ja
Publication of JP2018534311A5 publication Critical patent/JP2018534311A5/ja
Application granted granted Critical
Publication of JP6952691B2 publication Critical patent/JP6952691B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
JP2018525700A 2015-11-19 2016-11-18 Ｂ−ｒａｆ阻害剤及び免疫チェックポイント阻害剤を使用してがんを治療する方法 Active JP6952691B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562257645P 2015-11-19 2015-11-19
US62/257,645 2015-11-19
PCT/US2016/062859 WO2017087851A1 (en) 2015-11-19 2016-11-18 Methods of treating cancer using b-raf inhibitors and immune checkpoint inhibitors

Publications (3)

Publication Number Publication Date
JP2018534311A JP2018534311A (ja) 2018-11-22
JP2018534311A5 JP2018534311A5 (enExample) 2019-12-26
JP6952691B2 true JP6952691B2 (ja) 2021-10-20

Family

ID=57485956

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018525700A Active JP6952691B2 (ja) 2015-11-19 2016-11-18 Ｂ−ｒａｆ阻害剤及び免疫チェックポイント阻害剤を使用してがんを治療する方法

Country Status (12)

Country Link
US (3) US20180256552A1 (enExample)
EP (1) EP3377107B1 (enExample)
JP (1) JP6952691B2 (enExample)
KR (1) KR102702851B1 (enExample)
CN (2) CN108136022A (enExample)
AU (1) AU2016355320B2 (enExample)
ES (1) ES2824120T3 (enExample)
HK (1) HK1256367A1 (enExample)
IL (1) IL259055B (enExample)
MX (1) MX377351B (enExample)
PL (1) PL3377107T3 (enExample)
WO (1) WO2017087851A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA42971A (fr) 2015-03-13 2018-08-15 Cytomx Therapeutics Inc Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
EP3297672B1 (en) 2015-05-21 2021-09-01 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
BR112018011029A2 (pt) 2016-01-08 2018-11-21 Hoffmann La Roche métodos para tratar ou atrasar a progressão do câncer e para melhorar a função imune em um indivíduo com câncer, usos de um antagonista de ligação e de um anticorpo biespecífico, composições e kits
KR102530742B1 (ko) 2016-05-20 2023-05-09 하푼 테라퓨틱스, 인크. 단일 도메인 혈청 알부민 결합 단백질
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CN110914302A (zh) * 2017-06-01 2020-03-24 赛托姆克斯治疗学股份有限公司 可活化抗pdl1抗体及其使用方法
CA3078969A1 (en) 2017-10-13 2019-04-18 Harpoon Therapeutics, Inc. Trispecific proteins and methods of use
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
CN119306844A (zh) 2018-09-25 2025-01-14 哈普恩治疗公司 Dll3结合蛋白及使用方法
CN112867803A (zh) * 2018-10-16 2021-05-28 诺华股份有限公司 单独的或与免疫标志物组合的肿瘤突变负荷作为生物标志物用于预测对靶向疗法的应答
US20220288201A1 (en) * 2019-07-22 2022-09-15 H. Lee Moffitt Cancer And Research Institute, Inc. Combination therapy for treating ras-mutant cancers
WO2022131667A1 (ko) * 2020-12-18 2022-06-23 경희대학교 산학협력단 Oligodendrocyte transcription factor 2 억제제를 유효성분으로 포함하는 흑색종 치료 효과 증진용 약학적 조성물
CN117202897A (zh) * 2021-04-09 2023-12-08 基因泰克公司 使用raf抑制剂和pd-1轴抑制剂的组合疗法
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)
KR102974988B1 (ko) * 2023-06-27 2026-06-10 재단법인 아산사회복지재단 면역관문 억제제, 및 braf 억제제 및/또는 mek 억제제를 포함하는 braf-돌연변이 암 예방, 개선, 또는 치료용 조성물
CN121969385A (zh) 2023-09-11 2026-05-01 丹娜-法伯癌症研究院 含有il-2变体以增强car t细胞的功能性的car-衔接子
WO2025235862A1 (en) 2024-05-10 2025-11-13 Inndura Therapeutics Inc. A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
TW200639163A (en) 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
MY153898A (en) 2005-06-22 2015-04-15 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
NZ567140A (en) 2005-10-07 2011-09-30 Exelixis Inc Azetidines as MEK inhibitors for the treatment of proliferative diseases
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
CA2716947A1 (en) 2008-02-29 2009-09-11 Array Biopharma Inc. Imidazo [4,5-b] pyridine derivatives used as raf inhibitors
WO2009111278A2 (en) 2008-02-29 2009-09-11 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
AR072657A1 (es) 2008-02-29 2010-09-15 Genentech Inc Compuestos inhibidores de raf y metodos para su uso
US20110003859A1 (en) 2008-02-29 2011-01-06 Array Biopharma Inc. N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
DK2884979T3 (da) * 2012-08-17 2019-09-02 Hoffmann La Roche Kombinationsbehandlinger mod melanom omfattende indgivelse af cobimetinib og vemurafenib
WO2014193898A1 (en) * 2013-05-31 2014-12-04 Merck Sharp & Dohme Corp. Combination therapies for cancer
AU2014276440A1 (en) * 2013-06-03 2015-11-05 Novartis Ag Combinations of an anti-PD-L1 antibody and a MEK inhibitor and/or a BRaf inhibitor

Also Published As

Publication number Publication date
US20200155520A1 (en) 2020-05-21
WO2017087851A1 (en) 2017-05-26
CA3004348A1 (en) 2017-05-26
IL259055A (en) 2018-06-28
CN121154828A (zh) 2025-12-19
ES2824120T3 (es) 2021-05-11
CN108136022A (zh) 2018-06-08
AU2016355320A1 (en) 2018-05-17
HK1256367A1 (zh) 2019-09-20
IL259055B (en) 2022-05-01
US20180256552A1 (en) 2018-09-13
EP3377107A1 (en) 2018-09-26
MX377351B (es) 2025-03-07
KR20180081591A (ko) 2018-07-16
KR102702851B1 (ko) 2024-09-05
EP3377107B1 (en) 2020-08-12
JP2018534311A (ja) 2018-11-22
US20240115555A1 (en) 2024-04-11
AU2016355320B2 (en) 2023-12-07
MX2018006152A (es) 2018-09-17
PL3377107T3 (pl) 2020-12-14

Similar Documents

Publication Publication Date Title
EP3377107B1 (en) Methods of treating cancer using b-raf inhibitors and immune checkpoint inhibitors
JP2023524530A (ja) 免疫原性が低い癌の癌細胞死滅を増強するための３剤併用療法
US8992915B2 (en) Combination of CD37 antibodies with ICE
US20060134102A1 (en) Lymphotoxin beta receptor agents in combination with chemotherapeutic agents
CN113811332A (zh) 治疗al淀粉样变性的方法
KR20200078483A (ko) 간암 치료를 위한 조성물 및 방법
TW202003577A (zh) 用於在未曾接受過治療之個體治療癌症的標靶性TGF-β抑制之給藥方案
WO2017176565A1 (en) Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor
WO2022060678A1 (en) Combination therapy of a pd-1 antagonist and lag3 antagonist and lenvatinib or a pharmaceutically acceptable salt thereof for treating patients with cancer
TW202502382A (zh) 治療組合及其用途和治療方法
TW202502813A (zh) 包含偶聯物的藥物組合的治療方法和用途
CA3004348C (en) Methods of treating cancer using b-raf inhibitors and immune checkpoint inhibitors
KR20230136643A (ko) Al 아밀로이드증 치료 방법
US12599620B2 (en) Method for the treatment of chronic fatigue syndrome using an inhibitory or cytotoxic agent against plasma cells
TW202547553A (zh) 治療ａｌ類澱粉變性症之方法
TW202525861A (zh) 穩定的混合抗體的藥物組合物
WO2023198060A1 (zh) 蛋白酶体抑制剂与抗pd-1抗体的药物组合
TW202508632A (zh) 使用抗ｐｄ－１及化學療法治療肺癌
WO2026008043A9 (zh) 靶向Nectin-4的抗体药物缀合物和免疫检查点抑制剂联合的用途
WO2023185720A1 (zh) 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途
US20230086800A1 (en) Antibody fragments conjugated to peg-plga nanoparticles improve immunotherapy against cancer cells
WO2024002226A1 (zh) 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途
JP3845735B2 (ja) Ｃｄ４０ｌアンタゴニストを有効成分とする天疱瘡治療剤
HK40113732A (en) Methods and compositions comprising a shp2 inhibitor and a pd-l1 binding antagonist
WO2023160517A1 (zh) 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191118

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201027

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210427

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210831

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210928

R150 Certificate of patent or registration of utility model

Ref document number: 6952691

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250